argenex (NASDAQ:ARGX) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of argenex (NASDAQ:ARGX) from a hold rating to a buy rating in a report published on Saturday morning.

A number of other analysts have also recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. Oppenheimer upped their price objective on shares of argenex from $1,014.00 to $1,037.00 and gave the company an “outperform” rating in a report on Friday. Citizens Jmp dropped their price objective on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday. Weiss Ratings downgraded shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Finally, Glj Research raised shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,050.50.

argenex Price Performance

Shares of ARGX opened at $918.22 on Friday. The firm has a 50-day moving average of $868.28 and a 200-day moving average of $815.12. argenex has a one year low of $587.37 and a one year high of $953.58. The company has a market cap of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 70.27%. Analysts expect that argenex will post 26.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Sound Income Strategies LLC acquired a new stake in shares of argenex during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC acquired a new stake in shares of argenex in the 1st quarter valued at $28,000. Eastern Bank bought a new position in shares of argenex in the 2nd quarter valued at $32,000. Sunbelt Securities Inc. acquired a new stake in argenex in the third quarter valued at about $36,000. Finally, Axiom Investment Management LLC bought a new position in argenex in the first quarter valued at about $50,000. Institutional investors own 60.32% of the company’s stock.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.